XML 21 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues:      
Total revenues $ 1,774,758 $ 7,411,220 $ 4,111,930
Operating expenses:      
Research and development 249,240,324 94,245,436 88,017,319
General and administrative 53,752,353 37,247,828 27,203,156
Total operating expenses 302,992,677 131,493,264 115,220,475
Loss from operations (301,217,919) (124,082,044) (111,108,545)
Other income (expense):      
Interest income 3,363,080 3,311,846 2,605,981
Interest expense (1,936,447) (8,702,450) (7,948,539)
Change in fair value of derivative liability 0 (75,670,977) (1,763,652)
Gain (loss) on investment in affiliated entities (553,570) 36,556,658 (3,090,557)
Net unrealized gain (loss) on available-for-sale equity securities (3,222,838) 1,695,497 0
Other income (expense), net 343,371 (704,896) 496,200
Gain on deconsolidation of Geneos 0 4,121,075 0
Net loss before income tax benefit (303,224,323) (162,890,304) (120,809,112)
Income tax benefit 0 0 257,335
Share in net loss of Geneos (434,387) (4,584,610) 0
Net loss (303,658,710) (167,474,914) (120,551,777)
Net loss attributable to non-controlling interest 0 1,063,757 1,192,558
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (303,658,710) $ (166,411,157) $ (119,359,219)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders      
Basic (in USD per share) $ (1.45) $ (1.07) $ (1.21)
Diluted (in USD per share) $ (1.45) $ (1.07) $ (1.21)
Weighted average number of common shares outstanding      
Basic (in shares) 208,829,801 155,126,857 98,717,999
Diluted (in shares) 208,829,801 155,126,857 98,717,999
Convertible Bonds      
Other income (expense):      
Gain (loss) on extinguishment of convertible bonds and senior notes $ 0 $ (8,177,043) $ 0
6.50% Convertible Senior Notes Due 2024      
Other income (expense):      
Gain (loss) on extinguishment of convertible bonds and senior notes 0 8,762,030 0
Revenue under collaborative research and development arrangements      
Revenues:      
Total revenues 902,260 5,170,586 3,636,945
Revenue under collaborative research and development arrangements from affiliated entities      
Revenues:      
Total revenues 245,310 1,453,730 235,649
Other revenue      
Revenues:      
Total revenues 627,188 786,904 237,536
Other revenue from affiliated entities      
Revenues:      
Total revenues $ 0 $ 0 $ 1,800